Status:

COMPLETED

Diabetes Aerobic and Resistance Exercise (DARE) Study

Lead Sponsor:

Ottawa Hospital Research Institute

Collaborating Sponsors:

Canadian Institutes of Health Research (CIHR)

University of Ottawa

Conditions:

Diabetes Mellitus, Type 2

Diabetes Mellitus

Eligibility:

All Genders

40-70 years

Phase:

NA

Brief Summary

The main purpose of this study is to assess the impact of exercise training (aerobic exercise, resistance exercise, combined aerobic and resistance exercise) versus a sedentary waiting list control on...

Detailed Description

Background. The incidence of type 2 diabetes mellitus in the Western world is rising rapidly due to increases in obesity and sedentary behaviour, and diabetes is among the most potent common risk fact...

Eligibility Criteria

Inclusion

  • Type 2 diabetes mellitus as defined by the 1998 CDA Guidelines
  • Male or female
  • treated with diet and/or oral agents (no insulin)
  • age 40-70
  • HbA1c 0.066-0.099

Exclusion

  • Participation during the previous 6 months in a regular program of exercise or aerobic sports greater than 2 times per week for at least 20 minutes per session, or in any resistance training during the previous 6 months
  • Insulin therapy, or uncontrolled hyperglycemia (HbA1c\>0.099). Insulin therapy is an exclusion criterion because it would render HOMA insulin sensitivity calculation invalid.
  • Changes in medications for diabetes, BP or lipids in the 2 months prior to enrollment.
  • Significant weight change (increase or decrease of greater than 5% of body weight during the two months before enrollment).
  • Significant renal disease: serum creatinine greater than 200 mEq/l. or proteinuria \>1 g/24 hours.
  • Uncontrolled hypertension: BP \>160 mm Hg systolic or \>95 mm Hg diastolic BP in a sitting position.
  • Restrictions in physical activity due to disease: intermittent claudication, severe peripheral neuropathy or active proliferative retinopathy, unstable cardiac or pulmonary disease, disabling stroke, severe arthritis.
  • Other illness, judged by the patient or study physician to make participation in this study inadvisable.
  • Significant cognitive deficit resulting in inability to understand or comply with instructions.
  • Pregnancy at the start of the study, or intention to become pregnant in the next year.
  • Inability to communicate in English or French.
  • Unwillingness to sign informed consent.

Key Trial Info

Start Date :

September 1 1999

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2011

Estimated Enrollment :

251 Patients enrolled

Trial Details

Trial ID

NCT00195884

Start Date

September 1 1999

End Date

April 1 2011

Last Update

January 23 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Ottawa Hospital Research Institute

Ottawa, Ontario, Canada, K1H 7W9